| New Ways to Block UV Rays For fair skinned, light-eyed people, tanning isn't an option. But fair skin isn't the only risk factor for damage from the sun. Photosensitivity—an abnormally increased sensitivity to the sun's ultraviolet rays—can be brought on by certain medical conditions and many common medications. Here's what to watch out for. online.wsj.com |
4 Biotech Clearance Rack Stocks Joseph Krueger submits: The recent market volatility has really beaten down some biotech stocks. With the S&P, Dow, NASDAQ, and Russell 2000 down close to 5%, with some wild swings, the selling had been vicious. It seems that biotech stocks have taken a disproportional beating over this same period, shedding their aggressive gains seen in the first few months of this year in a very short time. This global can be represented by the losses in more popular biotech ETFs over the same time frame: IShares NASDAQ Biotechnology (IBB) is down 11%, First Trust AMEX Biotechnology (FBT) is down 13% , and finally the Biotech HOLDRs (BBH) is down 15%. Apart from individual factors for each company, the market’s woes are what probably caused an unprecedented ASCO sell-off this year, with the most popular ASCO stocks shedding 20% or more within a few days. What does this all mean? In a broad sense, nothing. Stocks go up and down for a variety of reasons, and what we have witnessed recently seems to be a culmination of overbought technicals, market conditions, cyclical patterns, ASCO, and the general summer doldrums. “Sell in May and go away”, they say. Although apparently exacerbated by the market’s troubles, this selloff should not have been a huge surprise: Many biotech stocks rise in anticipation of some key clinical data presented at ASCO, and tend to fade away when investors lose their enthusiasm. In fact, overall biotech stocks tend to have a cyclical pattern, where there is thought to be an established cycle to biotech where biotech stocks tend to rally in the last 3 months of the year (ending January/Feburary of the following year) and sell of slowly after that. An interesting analysis of this cycle is described here.Complete Story » seekingalpha.com |
Eight Trades on FDA, Clinical Trial Binary Events Mike Havrilla submits:Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news...On 7/9/10, Bristol-Myers (NYSE:BMY) announced that the FDA accepted its supplemental New Drug Application (sNDA) for a priority (six-month) review to expand the product label for SPRYCEL (dasatinib) (an oral BCR-ABL inhibitor anti-cancer agent) to include the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase.Complete Story » seekingalpha.com |
Cord Blood America Says Placenta Collection Services Increasing Revenues in Third Quarter; July 2010 Top Month in Year; BioCells, Inc. Acquisition Proceeding to September Closing [PR Newswire] - Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that placenta collection services in the third quarter of 2010 for a well-respected, accredited, tissue bank have increased by 40 percent so far compared to the second quarter of 2010, to a total of more than $35,000 in revenues through July and August of 2010. us.rd.yahoo.com |
Novartis MS Drug Wins Approval The Food and Drug Administration approved for sale the U.S. market's first oral drug to treat multiple sclerosis, in another sign of the improving picture for MS treatment. online.wsj.com |